Premature ovarian failure

Current Opinion in Obstetrics and Gynecology

Volumn 18, Issue 4, 2006, Pages 418-426

  Meskhi, Apollo ^a   Seif, Mourad W ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Hormonal (oestrogen) therapy; Oestrogen deficiency; Ovarian function; Ovarian reserve; Premature ovarian failure

Indexed keywords

BLEPHAROPHIMOSIS; CLINICAL FEATURE; FEMALE FERTILITY; FRAGILE X SYNDROME; GALACTOSEMIA; GONADAL DYSGENESIS; HIGH RISK POPULATION; HORMONAL THERAPY; HORMONE DEFICIENCY; ONSET AGE; OVARIAN FUNCTION TEST; PATHOGENESIS; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; SYMPTOMATOLOGY;

FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INFERTILITY, FEMALE; OVARIAN FAILURE, PREMATURE; OVARIAN FOLLICLE; REPRODUCTIVE TECHNIQUES, ASSISTED;

EID: 33745665583     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.gco.0000233937.36554.d3     Document Type: Review

References (163)

1. Rees M, Hope J, Stevenson J, British Menopause Society. Meeting the challenge of menopause 2005 http://www.the-bms.org/fact-sheet1.htm.
2. Nelson LM, Anasti JN, Flack MR. Premature ovarian ovarian failure. In: Adashi EY, Rock JA, Rosenwaks Z, editors. Reproductive Endocrinology, Surgery, and Technology. Philadelphia: Lippincott-Raven; 1996. pp. 1394-1410.
3. Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol 1986; 67:604-606.
4. Nelson LM, Anasti JN, Kimzey LM, et al. Development of luteinized graafian follicles in patients with karyotypically normal spontaneous premature ovarian failure. J Clin Endocrinol Metab 1994; 79:1470-1475.
5. Rebar RW, Erickson GF, Yen SSC. Idiopathic premature ovarian failure: Clinical and endocrine characteristics. Fertil Steril 1982; 37:35-41.
6. Richardson SJ, Senikas V, Nelson JF. Follicular depletion during the menopausal transition: Evidence for accelerated loss and ultimate exhaustion. J Clin Endocrinol Metab 1987; 65:1231-1237.
7. Richardson SJ, Nelson JF. Follicular depletion during the menopausal transition. Ann NY Acad Sci 1990; 592:13-20.
8. Cowchock FS, McCabe JL, Montgomery BB. Pregnancy after corticosteroid administration in premature ovarian failure (polyglandular endocrinopathy syndrome). Am J Obstet Gynecol 1988; 158:118-119.
9. Aiman J, Smentek C. Premature ovarian failure. Obstet Gynecol 1985; 66:9-14.
10. Alper MM, Jolly EE, Garner PR. Pregnancies after premature ovarian failure. Obstet Gynecol 1986; 67:59-62.
11. Ohsawa M, Wu MC, Masahashi T, et al. Cyclic therapy resulted in pregnancy in premature ovarian failure. Obstet Gynecol 1985; 66:64-67.
12. Polansky S, DePapp EW. Pregnancy associated with hypergonadotropic hypogonadism. Obstet Gynecol 1976; 47:47-51.
13. Shangold MM, Turksou RN, Bashford RA, et al. Pregnancy following the 'insensitive ovary syndrome'. Fertil Steril 1977; 28:1179-1181.
14. Szlachter BN, Nachtigall LE, Epstein J, et al. Premature ovarian failure: A reversible entity? Obstet Gynecol 1979; 54:396-398.
15. Jequier AM, Davis SR. The premature menopause: An example of a difficult diagnostic problem. In Programs and Abstracts of the Ist Australasian Menopause Society Congress, Perth, Australia, 1997.
16. Rebar RW, Connolly HV. Clinical features of young women with hypergonadotropic amenorrhea. Fertil Steril 1990; 53:804-810.
17. Nelson LM, Shawker TH, Merriam GR. Occult follicular development in patients with karyotypically normal spontaneous premature ovarian failure [abstract 693]. In Programs and Abstracts of the 72nd Annual Meeting of the Endocrine Society, Atlanta, Georgia, 1990.
18. Davis SR. Premature ovarian failure. Maturitas 1996; 28:1-8.
19. Rebar RW, Cedars MI. Hypergonadotropic forms of amenorrhea in young women. Endocrinol Metab Clin North Am 1992; 21:173-191.
20. Jacobsen BK, Heuch I, Kvale G. Age at natural menopause and all-cause mortality: a 37-year follow-up of 19,731 Norwegian women. Am J Epidemiol 2003; 157:923-929.
21. Van Der Schouw YT, Van Der Graaf Y, Steyerberg EW, et al. Age at menopause as a risk for cardiovascular mortality. Lancet 1996; 347:714-718.
22. van Der Voort DJ, van Der Weijer PH, Barentsen R. Early menopause: increased fracture risk at older age. Osteoporos Int 2003; 14:525-530.
23. Snowdon DA, Kane RL, Beeson WL, et al. Is early natural menopause a biologic marker of health and aging? Am J Public Health 1989; 79:709-714.
24. Anasti JN, Kalantaridou SN, Kimzey LM, et al. Bone loss in young women with karyotypically normal spontaneous premature ovarian failure. Obstet Gynecol 1998; 91:12-15.
25. Bagur AC, Mautalen CA. Risk for developing osteoporosis in untreated premature menopause. Calcif Tissue Int 1992; 51:4-7.
26. Conway GS, Kaltsas G, Patel A, et al. Characterization of idiopathic premature ovarian failure. Fertil Steril 1996; 65:337-341.
27. Ohta H, Sugimoto I, Masuda A, et al. Decreased bone mineral density associated with early menopause progresses for at least ten years: Cross-sectional comparisons between early and normal menopausal women. Bone 1996; 18:227-231.
28. Colditz GA, Willett WC, Stampfer MJ, et al. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987; 316:1105-1110.
29. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. Lancet 1993; 341:72-75.
30. Duncan M, Cummings L, Chada K. Germ cell deficient (gcd) mouse as a model of premature ovarian failure. Biol Reprod 1993; 49:221-227.
31. Bannatyne P, Russell P, Sherman RP. Autoimmune oophoritis: A clinico-pathologic assessment of 12 cases. Int J Gynecol Pathol 1990; 9:191-207.
32. Irvine WJ, Chan MMW, Scarth L, et al. Immunological aspects of premature ovarian failure associated with idiopathic Addison's disease. Lancet 1968; 2:7574-7890.
33. Sedmak DD, Hart WR, Tubbs RR. Autoimmune oophoritis: A histopathologic study of involved ovaries with immunologic characterization of the mononuclear cell infiltrate. Int J Gynecol Pathol 1987; 6:73-89.
34. Coulam CB, Ryan RJ. Premature menopause I etiology. Am J Obstet Gynecol 1979; 133:639-643.
35. Forges T, Monnier-Barbarino P, Faure GC, Bene MC. Autoimmunity and antigenic targets in ovarian pathology. Hum Reprod Update 2004; 10:163-175.
36. Nelson LM, Kimzey LM, Merriam GR, et al. Increased peripheral T lymphocyte activation in patients with karyotypically normal spontaneous premature ovarian failure. Fertil Steril 1991; 55:1082-1087.
37. Wolfe CD, Stirling RW. Premature menopause associated with autoimmune oophoritis: Case report. Br J Obstet Gynaecol 1988; 95:630-632.
38. Kim TJ, Anasti JN, Flack MR, et al. Routine endocrine screening for patients with karyotypically normal spontaneous premature ovarian failure. Obstet Gynecol 1997; 89:777-779.
39. Ryan MM, Jones HR Jr. Myasthenia gravis and premature ovarian failure. Muscle Nerve 2004; 30:231-233.
40. Balen A. Reproductive Endocrinology for the MRCOG and beyond. 1st ed. London: RCOG Press; 2003.
41. Monnier-Barbarino P, Forges T, Faure GC, Bene MC. Gonadal antibodies interfering with female reproduction. Best Pract Res Clin Endocrinol Metab 2005; 19:135-148.
42. Drexhage HA, Bottazzo GF, Bitensky L, et al. Thyroid growth-blocking antibodies in primary myxoedema. Nature 1981; 289:594-596.
43. Lindstrom JM, Seybold ME, Lennon VA, et al. Antibody to acetylcholine receptor in myasthenia gravis: Prevalence, clinical correlates, and diagnostic value. Neurology 1976; 26:1054-1059.
44. Nagamine K, Peterson P, Scott HS. Positional cloning of the APECED gene. Nat Genet 1997; 17:393-398.
45. The Finish-German APECED Consortium. An autoimmune disease, APECED, caused by mutations in a novel gene featuring two PHD-type zinc-finger domains. Nat Genet 1997; 17:399-403.
46. Neufeld M, Maclaren NK, Blizzard RM. Two types of autoimmune Addison's disease associated with different polyglandular autoimmune (PGA) syndromes. Medicine 1981; 60:355-359.
47. Laml T, Preyer O, Umek W, et al. Genetic disorders in premature ovarian failure. Hum Reprod Update 2002; 8:4834-4891.
48. Ahonen P, Koskimies S, Lokki ML, et al. The expression of autoimmune polyglandular disease type 1 appears associated with several HLA-A antigens but not with HLADR. J Clin Endocrinol Metab 1988; 66:1152-1157.
49. Ahonen P, Myllarniemi S, Sipila I, et al. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med 1990; 322:1829-1836.
50. Wheatcroft N, Weetman AP. Is premature ovarian failure an autoimmune disease? Autoimmunity 1997; 25:157-165.
51. Maclaren N, Chen QY, Kukreja A, et al. Autoimmune hypogonadism as part of an autoimmune polyglandular syndrome. J Soc Gynecol Investig 2001; 8:S52-S54.
52. Toledo SPA, Brunner HG, Kraaij R, et al. An inactivating mutation of the luteinizing hormone receptor causes amenorrhea in a 46,XX female. J Clin Endocrinol Metab 1996; 81:3850-3854.
53. Matthews CH, Borgato S, Beck-Peccoz P, et al. Primary amenorrhoea and infertility due to a mutation in the subunit of follicle-stimulating hormone. Nat Genet 1993; 5:83-86.
54. Aittomaki K, Lucena JLD, Pakarinen P, et al. Mutation in the follicle-stimulating hormone receptor gene causes hereditary hypergonadotrophic ovarian failure. Cell 1995; 82:959-968.
55. Sundblad V, Chiauzzi VA, Escobar ME, et al. EH Screening of FSH receptor gene in Argentine women with premature ovarian failure. Mol Cell Endocrinol 2004; 30:1-2.
56. Aittomaki K, Herva R, Stenman UH, et al. Clinical features of primary ovarian failure caused by a point mutation in the follicle-stimulating hormone receptor gene. J Clin Endocrinol Metab 1996; 81:3722-3726.
57. Simpson JL, Christakos AC, Horwith M, et al. Gonadal dysgenesis in individuals with apparently normal chromosomal complements: Tabulation of cases and compilation of genetic data. Birth Defects 1971; 7:215-228.
58. Latronico AC, Anasti JN, Arnhold IJP, et al. Brief report: Testicular and ovarian resistance to luteinizing hormone caused by inactivating mutations of the luteinizing hormone-receptor gene. N Engl J Med 1996; 334:507-512.
59. Kater CE, Biglieri EG. Disorders of steroid 17 alpha-hydroxylation deficiency. Endocrinol Metab Clin North Am 1994; 23:341-357.
60. Zachmann M. Defects in steroidogenic enzymes: Discrepancies between clinical steroid research and molecular biology results. J Steroid Biochem Mol Biol 1995; 53:159-164.
61. Bachelot A, Meduri G, Massin N, et al. Ovarian steroidogenesis and serum androgen levels in patients with premature ovarian failure. J Clin Endocrinol Metab 2005; 90:2391-2396 [epub: 25 Jan 2005].
62. Pellicer A, Miro F, Sampaio M, et al. In vitro fertilization as a diagnostic and therapeutic tool in a patient with partial 17,20 desmolase deficiency. Fertil Steril 1991; 55:970-975.
63. Rabinovici J, Blankstein J, Goldman B, et al. In vitro fertilization and primary embryonic cleavage are possible in 17a-hydroxylase deficiency despite extremely low intrafollicular 17(b-estradiol. J Clin Endocrinol Metab 1989; 68:693-697.
64. Meirow D, Schenker JG, Resler A. Ovarian hyperstimulation syndrome with low oestradiol in nonclassical 17 a-hydroxylase, 17,20 lyase deficiency: What is the role of oestrogens? Hum Reprod 1996; 11:2119-2221.
65. Forges T, Monnier-Barbarino P. Premature ovarian failure in galactosaemia: pathophysiology and clinical management. Pathol Biol (Paris) 2003; 51:47-56.
66. Coulam CB, et al. Incidence of premature ovarian failure. JF Obstet Gynecol 1986; 67:604-606.
67. Migeon BR, Jelalian K. Evidence for two active X chromosomes in germ cells of female before meiotic entry. Nature 1977; 269:242-243.
68. Singh RP, Carr DH. The anatomy and histology of XO human embryos and fetuses. Anat Rec 1966; 155:369-384.
69. Sarto GE. Cytogenetics of fifty patients with primary amenorrhea. Am J Obstet Gynecol 1974; 119:14-23.
70. Brown CJ, Lafreniere RG, Powers VE, et al. Localization of the X inactivation centre on the human X chromosome in Xq13. Nature 1991; 349:82-84.
71. Powell CM, Taggart RT, Drumheller TC, et al. Molecular and cytogenetic studies of an X autosome translocation in a patient with premature ovarian failure and review of the literature. Am J Med Genet 1994; 52:19-26.
72. Therman E, Laxova R, Susman B. The critical region on the human Xq. Hum Genet 1990; 85:455-461.
73. Kok HS, van Asselt KM, van der Schouw YT, et al. Genetic studies to identify genes underlying menopausal age. Hum Reprod Update 2005; 11:483-493. This study reviews genetic factors associated with a spectrum of menopausal age, and gives an overview of the candidate gene studies which may improve our understanding of the role of genetic and environmental factors and advance prevention and treatment of the disease.
74. Luoma P, Melberg A, Rinne JO, et al. Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. Lancet 2004; 364:875-882.
75. Murray A. Premature ovarian failure and the FMR1 gene. Semin Reprod Med 2000; 18:59-66.
76. Bondy CA, Nelson LM, Kalantaridou SN. The Genetic origins of ovarian failure. J Womens Health 1998; 7:1225-1229.
77. Sala C, Arrigo G, Torri G, et al. Eleven X chromosome breakpoints associated with premature ovarian failure (POF) map to 15-Mb YAC contig spanning Xg21. Genomics 1997; 40:123-131.
78. National Institute of Health National Institute of Child Health, and Human Development. Epub, Available from: http://www.nichd.nih.gov/publications/ pubs/fragileX/sub12.htm (Last Modified: 05/05/2004).
79. Murray A, Webb J, MacSwiney F, et al. Serum concentrations of follicle stimulating hormone may predict premature ovarian failure in FRAXA premutation women. Hum Reprod 1999; 14:1217-1218.
80. Fast D, Abrams LJ, Summary of Fragile X Syndrome; Prevalence of fragile X syndrome, Available from: http://www.fragilex.org/html/summary.htm.
81. Bussani C, Papi L, Sestini R, et al. Premature ovarian failure and fragile X premutation: a study on 45 women. Eur J Obstet Gynecol Reprod Biol 2004; 112:189-191.
82. Bruneteau DW, Sipahioglu IB, Byrd JR, Greenblatt RB. Pure gonadal dysgenesis with an XY chromosomal constitution (Swyer's syndrome): Report of two cases. Am J Obstet Gynecol 1976; 124:55-59.
83. Minto CL, Crouch NS, Conway GS, Creighton SM. XY Females: Revisiting the Diagnosis. BJOG 2005; 112:1407-1410.
84. Imai A, Horibe S, Fuseya T, et al. Detection of SRY in a 46,XY female (Swyer's syndrome. J Med 1997; 28:49-54.
85. Swyer's Syndrome. Available from: http://www.uclh.nhs.uk/NR/rdonlyres/ 07C53DB9-6C67-4375-86B4-DB9DF42635AD/21986/SwyersSyndrome.pdf.
86. Beysen D, De Baere E, Blepharophimosis, Ptosis, and Epicanthus Inversus. [BPES, Blepharophimosis Syndrome. Includes: Blepharophimosis, Ptosis, and Epicanthus Inversus Type I (BPES I); Blepharophimosis, Ptosis, and Epicanthus Inversus Type II (BPES II)] Last update: 12 July 2005. Available from: http://www.geneclinics.org/servlet/access?db=geneclinics&site= gt&id=8888891&key=yvyThuThGZXK5&gry=&fcn=y&fw= suti&filename= /profiles/bpes/index.html.
87. Loffler KA, Zarkower D, Koopman P. Etiology of ovarian failure in blepharophimosis ptosis epicanthus inversus syndrome: FOXL2 is a conserved, early-acting gene in vertebrate ovarian development. Endocrinology 2003; 144:3237-3243.
88. McKusick VA, Gonadal dysgenesis, XX type, with deafness. 6/3/1986 Perrault Syndrome. Ovarian dysgensis with sensorineural deafness. Available from: http://srs.embl-heidelberg.de:8000/srs5bin/cgi-bin/wgetz?-e+% 5Bomim-id:233400%5D.
89. Bellassoued M, et al. Perrault's syndrome: two cases. Ann Endocrinol (Paris) 2001; 62:534-537.
90. Vermeulen A. Environment, human reproduction, menopause, and andropause. Environ Health Perspec 1993; 101:91-100.
91. Morrison JC, Givens JR, Wiser WL, et al. Mumps oophoritis: A cause of premature menopause. Fertil Steril 1975; 26:655-659.
92. Molina JR, Barton DL, Loprinzi CL. Chemotherapy-induced ovarian failure (Manifestations and management). Drug Safety 2005; 28:401-416. Excellent information about different aspects of chemotherapy-induced ovarian failure and modern options of their management.
93. Familiari GA, Caggiatti A, Nottola SA, et al. Ultrastructure of human ovarian primordial follicles after combination chemotherapy for Hodgkin's disease. Hum Reprod 1993; 8:2080-2087.
94. Larsen EC, Müller J, Schmiegelow K, et al. Reduced ovarian function in long-term survivors of radiation- and chemotherapy-treated childhood cancer. J Clin Endocrinol Metab 2003; 88:5307-5314.
95. Radford JA, Shalet SM, Lieberman BA. Fertility after treatment for cancer. BMJ 1999; 319:935-936.
96. Meirow D. Ovarian injury and modern options to preserve fertility in female cancer patients treated with high dose radio-chemotherapy for hemato-oncological neoplasias and other cancers. Leuk Lymphoma 1999; 33:65-76.
97. Beerendonk CCM, Braat DDM. Present and future options for the preservation of fertility in female adolescents with cancer. Endocr Dev 2005; 8:166-175. In this article factors influencing gonadotixicity are dicussed and ways of minimizing their effect on gonadal function are evaluated.
98. Howell S, Shalet S. Gonadal damage from chemotherapy and radiotherapy. Endocrinol Metab Clin North Am 1998; 27:927-943.
99. Meirow D. Reproduction post chemotherapy in young cancer patients. Mol Cell Endocrinol 2000; 27:123-131.
100. Müller J. Disturbance of pubertal development after cancer treatment. Best-Pract-Res Clin Endocrinol Metab 2002; 16:91-103.
101. Koyama H, Wada T, Nishizawa Y, et al. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 1977; 39:1403-1409.
102. Bath LE, Tydeman G, Critchley HOD, et al. Spontaneous conception in a young woman who had ovarian cortical tissue cryopreserved before chemotherapy and radiotherapy for a Ewing's sarcoma of the pelvis: case report. Hum Reprod 2004; 19:2569-2572.
103. Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update 2001; 7:535-543.
104. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996; 14:1718-1729.
105. Marmor D. Fertilité féminine après traitement anticancéreux [Fertility in women after cancer therapy]. Contracept Fertil Sex 1999; 27:417-422.
106. Schuck A, Hamelmann V, Brämswig JH, et al. Ovarian function following pelvic irradiation in prepubertal and pubertal girls and young adult women. Strahlenther Onkol 2005; 181:534-539.
107. Sklar C. Maintenance of ovarian function and risk of premature menopause related to cancer treatment. J Natl Cancer Inst Monogr 2005; 34:25-27.
108. Wallace WHB, Thomson AB, Saran F, Kelsey TW. Predicting age of ovarian failure after radiation to a field that includes the ovaries. Int J Radiat Oncol Biol Phys 2005; 62:738-744. The authors evaluate model of predicting the age of POF after treatment with a known dose of radiotherapy. This could enable clinicians to counsel women on their reproductive potential after treatment.
109. Muller J. Disturbance of pubertal development after cancer treatment. Best Pract Res Clin Endocrinol Metab 2002; 16:91-103.
110. Kiess W, Conway G, Ritzen M, et al. Induction of puberty in the hypogonadal girl-practices and attitudes of pediatric endocrinologists in Europe. Horm Res 2002; 57:66-71.
111. Kalantaridou SN, Davies SR, Nelson LM. Premature ovarian failure. Endocrinol Metab Clin North Am 1998; 27:989-1006.
112. Ewertz M, et al. Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study. Br J Cancer 2005; 92:1293-1297.
113. Maas AHEM. The lost promise of hormone replacement therapy and heart disease. Semin Vasc Med 2004; 4:135-144.
114. Harman SM, Brinton EA, Clarkson T, et al. Is the WHI relevant to HRT started in the perimenopause? Endocrine 2004; 24:195-202.
115. Bruce IN. 'Not only...but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus. Rheumatology (Oxford) 2005; 44:1492-1502.
116. Zayas JFJ, Elizondo ALJ, Ramirez AJA, Montoya VCA. Evaluation of the bone mass in the different types of menopause. Ginecol Obstet Mex 2003; 71:118-123.
117. Jeandel C. Postmenopausal osteoporosis diagnostic methods and their indications. Rev Med Interne 2004; 25:S538-S542.
118. Kreiner D, Droesch K, Navot D, et al. Spontaneous and pharmacologically induced remissions in patients with premature ovarian failure. Obstet Gynecol 1988; 73:926-928.
119. Davison SL, Bell R, Donath S, et al. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005; 90:3847-3853.
120. Papalia MA, Davis SR. What is the rationale for androgen therapy for women? Treat Endocrinol 2003; 2:77-84.
121. Arlt W. Management of the androgen-deficient woman. Growth Horm IGF Res 2003; 13:S85-S89.
122. Davis SR, Burger HG. The role of androgen therapy. Best Pract Res Clin Endocrinol Metab 2003; 17:165-175.
123. Borer KT. Physiscal activity in the prevention and amelioration of osteoporosis in women: interaction of mechanical, hormonal and dietary factors. Sports Med 2005; 35:779-830.
124. Di Daniele N, Carbonelli MG, Candeloro N, et al. Effect of supplementation of calcium and vitamin D on bone mineral density and bone mineral content in peri- and postmenopause women; a double-blind, randomized, controlled trial. Pharmacol Res 2004; 50:637-641.
125. Graziottin A, Basson R. Sexual dysfunction in women with premature menopause. Menopause 2004; 11:766-777.
126. Simon J, Braunstein G, Nachtigall L, et al. Testosterone patch increases sexual activity and desire in surgically menopausal women with hypoactive sexual desire disorder. J Clin Endocrinol Metab 2005; 90:5226-5233.
127. Braunstein GD, Sundwall DA, Katz M, et al. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med 2005; 165:1582-1589.
128. Somboonpom W, Davies S, Seif MW, Bell R. The Cochran Database of Systematic Reviews 2005; Art NoCD004509.DOI:10.1002/14651858. CD004509.pub2.
129. Arlt W. Dehydroepiandrosterone replacement therapy. Semin Reprod Med 2004; 22:379-388.
130. Million Women Study, Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362:419-427.
131. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321-333.
132. Loh FH. Use of hormone replacement therapy in the asymptomatic postmenopausal woman: what is the current evidence? Ann Acad Med Singapore 2003; 32:605-610.
133. van-Kasteren YM. Prematuur ovarieel fallen [Premature ovarian failure]. Ned-Tijdschr Geneeskd 2000; 144:2142-2146.
134. Johnson TR, Peterson EP. Gonadotropin induced pregnancy following 'premature ovarian failure'. Fertil Steril 1979; 31:351-352.
135. Shapiro AG, Rubin A. Spontaneous pregnancy in association with hypergonadotropic ovarian failure. Fertil Steril 1977; 28:500-501.
136. Van Kasteren YM, Hoek A, Schoemaker J. Ovulation induction in premature ovarian failure: A placebo-controlled randomized trial combining pituitary suppression with gonadotropin stimulation. Fertil Steril 1995; 64:273-278.
137. Foresight preconception. IVF success rate 2000 [Online]. 2005 [Cited 2002]. Available from: http://www.foresight-preconception.org.uk/news-views/ IVFstats1.html.
138. Lydic ML, Liu JH, Rebar RW. Success of donor oocyte in in vitro fertilization embryo transfer in recipients with and without premature ovarian failure. Fertil Steril 1996; 65:98-102.
139. Morris RS, Sauer MV. New advances in the treatment of infertility in women with ovarian failure. Curr Opin Obstet Gynecol 1993; 5:368-377.
140. Navot D, Drews MR, Bergh PA, et al. Age-related decline in female fertility is not due to diminished capacity of the uterus to sustain embryo implantation. Fertil Steril 1994; 61:97-101.
141. Sauer MV, Paulson RJ, Lobo RA. Reversing the natural decline in human fertility. JAMA 1992; 268:1275-1279.
142. Sung L, Bustillo M, Mukherjee T, et al. Sisters of women with premature ovarian failure may not be ideal ovum donors. Fertil Steril 1997; 67:912-916.
143. Falcone T, Bedaiwy MA. Fertility preservation and pregnancy outcome after malignancy. Curr Opin Obstet Gynecol 2005; 17:21-26.
144. Howell SJ, Shalet SM. Fertility preservation and management of gonadal failure associated with lymphoma therapy. Curr Oncol Rep 2002; 4:443-452.
145. Morice P, Juncker L, Rey A, et al. Ovarian transposition for patients with cervical carcinoma treated by radiosurgical combination. Fertil-Steril 2000; 74:743-748.
146. Tinga DJ, Dolsma WV, Tamminga RY, van-der-Zee AG. Behoud van de ovariële functie bij 2 jonge vrouwen met de ziekte van Hodgkin, door laparoscopische transpositie van de ovaria voorafgaand aan abdominale bestraling [Preservation of ovarian function in 2 young women with Hodgkin disease by laparoscopic transposition of the ovaries prior to abdominal irradiation]. Ned Tijdschr Geneeskd 1999; 143:308-312.
147. Smitz J, Cortvrindt R. First childbirth from transplanted cryopreserved ovarian tissue brings hope for cancer survivors. Lancet 2004; 364:1379-1380.
148. Hovatta O. Cryopreservation and culture of human ovarian cortical tissue containing early follicles. Eur J Obstet Gynecol Reprod Biol 2004; 5 (Suppl 1): S50-S54.
149. Oktay K, Buyuk E. Ovarian transplantation in humans: indications, techniques and the risk of reseeding cancer. Eur J Obstet Gynecol Reprod Biol 2004; 113:S45-S47.
150. Posada MN, Kolp L, Garcia JE. Fertility options for female cancer patients: facts and fiction. Fertil Steril 2001; 75:647-653.
151. Donnez J, Dolmans MM, Demylle D, et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 2004; 364:1405-1410.
152. Poirot C, Vacher-Lavenu MC, Helardot P, et al. Human ovarian tissue cryopreservation: indications and feasibility. Hum Reprod 2002; 17:1447-1452.
153. Silber-Sherman J, Lenahan KM, Levine DJ, et al. Ovarian transplantation between monozygotic twins discordant for premature ovarian failure. N Engl J Med 2005; 353:58-63.
154. Lutchman Singh K, Davies M, Chatterjee R. Fertility in female Cancer Survivors: pathophysiology, preservation and the role of ovarian reserve testing. Human Reproduction Update 2005; 11:69-89.
155. Nikolaou D, Templeton A. Early ovarian ageing: a hypothesis detection and clinical relevance. Hum Reprod 2003; 18:1137-1139.
156. Nikolaou D, Templeton A. Early ovarian ageing. Eur J Obstet Gynecol Reprod Biol 2004; 113:126-133.
157. Overlie I, Mørkrid L, Andersson AM, et al. Study of hormonal changes during the menopausal transition. Acta Obstet Gynecol Scand 2005; 84:281-285.
158. van Rooij IAJ, Tonkelaar I-den, Broekmans FJM, et al. Antimüllerian hormone is a promising predictor for the occurrence of the menopausal transition. Menopause 2004; 11:601-606.
159. Hall JE. Neuroendocrine physiology of the early and late menopause. Endocrinol-Metab Clin North Am 2004; 33:637-659.
160. Gracia CR, Sammel MD, Freeman EW, et al. Defining menopause status: creation of a new definition to identify the early changes of the menopausal transition. Menopause 2005; 12:128-135.
161. de Boer EJ, den Tonkelaar I, te Velde ER, et al. Corporate author OMEGA-project group. Increased risk of early menopausal transition and natural menopause after poor response at first IVF treatment. Hum Reprod 2003; 18:1544-1552.
162. Lutchman SK, Davies M, Chatterjee R. Fertility in female cancer survivors: pathophysiology, preservation and the role of ovarian reserve testing. Hum Reprod Update 2005; 11:69-89 [epub: 29 Nov 2004].
163. Nelson LM, Covington SN, Rebar RW. An update: spontaneous premature ovarian failure is not an early menopause. Fertil Steril 2005; 83:1327-1332. An excellent update for clinicians regarding the management of women with spontaneous premature ovarian failure, which underlies importance of an integrated approach.